The Aporia
Hynds, J. (2026, October 22). World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist. Daily Mail. https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
Hynds, Joanna. “World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist.” Daily Mail, 22 Oct. 2026, https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490.
Hynds, Joanna. “World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist.” Daily Mail, October 22, 2026. https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490.
Dated from the outlet's own feed. Check the original for its byline.
Moderna and MSD developed intismeran, a personalized mRNA-based vaccine, which when combined with Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% in patients two years after surgery. The trial included over 1,100 participants with high-risk melanoma that had been surgically removed. Intismeran targets up to 34 tumor neoantigens specific to each patient's tumor, enhancing the immune system’s ability to fight cancer. Although results are promising and could mark a turning point in personalized cancer treatment, longer-term studies are needed to confirm long-term benefits and impact on overall survival rates. The vaccine is currently experimental and not available on healthcare systems like NHS yet. Similar approaches are being tested for other cancers including kidney, bladder, and lung cancer. The detailed findings were initially scheduled to be presented at the European Society of Medical Oncology Congress but were released ahead of time due to data leaks. Lead researcher Professor Georgina Long from Melanoma Institute Australia described the results as "phenomenal" and potentially transformational for cancer treatment. Independent experts also view the outcome positively, though they emphasize the need for extended follow-up studies to establish definitive benefits in patient longevity.